Researchers found that adding thyroid hormone T3 to standard chemotherapy can suppress tumor regrowth and extend survival in medulloblastoma patients. The study used laboratory and animal models, showing promise for a new treatment approach.
The Temple Family Thriving Program integrates caregiver and early childhood support into prenatal and postpartum care to strengthen parent-child bonds and promote healthy development. The program aims to reduce risk factors associated with child abuse and neglect by addressing caregiver stress and promoting positive parenting practices.
Researchers have tested a new experimental cancer drug called gamitrinib in its first-in-human study. Gamitrinib is designed to target the mitochondria of cancer cells, where it can disrupt their energy systems.
A new composite scoring system, HOST-Factor, quantifies the functional state of the tumor microenvironment in pancreatic cancer. The study demonstrates the effectiveness of pulsed low-dose-rate chemoradiation in shifting the tumor microenvironment from a tumor-promoting to a tumor-restricting state.
Researchers found that younger mice had lower cancer spread, while middle-aged mice were more likely to experience aggressive melanoma. Middle-aged mice also had fewer immune cells called gamma delta (γδ) T cells, which help prevent cancer from spreading.
Researchers found that circulating tumor DNA can predict metastatic risk in patients treated with bladder-sparing treatment for muscle-invasive bladder cancer. The absence of ctDNA predicted favorable outcomes regardless of bladder removal status.
A new study from Fox Chase Cancer Center confirms that preoperative radiation therapy does not reduce surgical complexity in patients with retroperitoneal sarcoma. The research suggests that most patients benefit from proceeding directly to surgery, as skipping radiation has no significant impact on tumor size or surgical outcomes.
The partnership enables Fox Chase to implement clinical testing utilizing Arima's 3D-genomics technology for multiple tumor types, guiding diagnosis and treatment. This collaboration accelerates innovation through strategic partnerships integrating basic science, clinical research, and patient care.
A Fox Chase Cancer Center study found that outpatient observation significantly reduced hospital stays with no adverse safety events reported. The structured model also freed up inpatient beds and cut healthcare costs.
A study found that measuring a patient's absolute lymphocyte count can predict their response to CAR T-cell therapy for non-Hodgkin lymphoma. Patients with higher lymphocyte counts and faster increases tend to have better outcomes, including progression-free survival and overall survival.
Researchers have uncovered a new mechanism by which the body's immune system responds to viral infections, potentially leading to a new approach for fighting cancer. The study reveals that infected cells produce their own unique RNA signal, Z-RNA, which sets off a chain reaction leading to cell death before viruses can hijack them.
Researchers at Fox Chase Cancer Center demonstrate that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce severe side effects, such as painful swallowing problems, while maintaining treatment effectiveness for patients with esophageal and non-small cell lung cancer. The study's key findings show that PLDR brea...
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
A study published in European Urology predicts a doubling of kidney cancer cases worldwide over the next 25 years. Modifiable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension are expected to drive this rise.
The BREATHE-3 clinical trial evaluates a novel bronchoscopic device to open airways and release trapped air in patients with severe emphysema. The study will assess the safety and efficacy of the Apreo BREATHE Airway Scaffold, an implantable device granted FDA Breakthrough Device Designation.
Researchers discovered cancer cells can survive within bone marrow fibroblasts in response to BTK inhibitors, leading to higher survival rates. By blocking CXCR4, treatment may become more effective, potentially increasing complete response rates and moving toward a cure for cancer
Researchers identified a new strategy to repair damaged heart tissue by reactivating the PSAT1 gene through synthetic modified messenger RNA. The study found that mice treated with PSAT1-modRNA showed robust increases in cardiomyocyte proliferation, reduced tissue scarring, and improved heart function.
Researchers at Fox Chase Cancer Center have provided a detailed assessment of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging. The study found that upstaging rates associated with delays are relatively small and consistent with prior data.
Researchers discovered that breast cancer responds to CDK4/6 inhibitors by forming an immunosuppressive microenvironment, which can be mitigated with radiation therapy or immune-modulating drugs. The study also found a potential biomarker to predict treatment response in patients.
Researchers have identified a specific KRAS mutation, KRAS G12V, that may be targeted therapeutically to treat colon cancer. This mutation can be selectively inhibited using ACSS2 enzyme, potentially creating new therapeutic targets for personalized medicine.
Patients with metastatic colorectal cancer treated with biweekly TAS-102 showed similar treatment effectiveness while experiencing reduced toxicity and lower rates of myelosuppression compared to standard dosing. This alternative schedule may be particularly useful for older patients or those with chemotherapy-related toxicities.
A novel screening approach called VEST uses virtual echocardiography to identify patients at high risk of pulmonary arterial hypertension, a life-threatening form of heart failure. The tool has been shown to generate accurate PAH risk scores without manual calculations and can guide timely referrals for expert care.
A new study from Fox Chase Cancer Center researchers found that implementing a Best Practice Advisory in the electronic medical record system increased oncofertility referrals by 450%. This led to 14 successful fertility preservation cases within six months, compared to just 22 in the previous five years.
Researchers at Fox Chase Cancer Center discovered that talin has distinct binding modes for two types of integrins in blood cells, which could enhance their function and lead to more effective treatments. The study highlights the importance of understanding how talin interacts with different integrin subtypes to modulate its activity.
Researchers at Fox Chase Cancer Center found that fragmented care does not negatively impact survival outcomes for retroperitoneal sarcoma patients. Despite longer travel distances and delays between diagnosis and treatment, patients receiving nonfragmented care had equivalent overall survival rates as those with non-fragmented care.
A harmful form of tau protein directly damages blood vessels in the brain, leading to inflammation and weakening the brain's protective shield. The discovery highlights the importance of focusing on early neurovascular changes mediated by tau to prevent or slow down damage to the blood-brain barrier.
Scientists have discovered a novel regulator of the mitochondrial sodium-calcium exchanger (NCLX), which helps maintain calcium balance in mitochondria. The discovery of TMEM65 could lead to new therapeutic agents to combat calcium overload associated with heart failure and Alzheimer's disease.
Researchers at Temple University have discovered a new way to block the enzyme DLK, which plays a key role in neurodegenerative diseases. The breakthrough approach protects damaged neurons while preserving healthy neuron function.
The school aims to implement evidence-based practice and reduce antibiotic misuse in pediatric populations. The PCORI funding will support work with physicians, families, and providers to delay unnecessary antibiotics.
Scientists have identified a critical genetic mechanism driving cardiac fibrosis and found a novel target for its reversal. The discovery sheds light on the role of transforming growth factor-beta (TGFβ) and ATP-citrate lyase (ACLY) in promoting excessive tissue scarring, providing hope for new heart failure treatments.
Researchers at the Lewis Katz School of Medicine will investigate how injured heart cells communicate with other cells throughout the body using microvesicles known as exosomes. The study aims to understand how specific molecules, such as microRNAs, facilitate communication pathways between cells in the heart and vasculature.
Researchers led by Dr. Victor Luna aim to develop new treatments for late-life depression and Alzheimer's disease by understanding how synapses function in the aging brain. They will investigate the role of a synaptic protein called mGluR2 in memory formation and emotion.
New studies published in Preventive Medicine Reports and BMC Public Health found that segments about community firearm violence on local television news are often demographically and geographically unrepresentative. They also frequently contain harmful elements, such as blame of victims or reinforcement of racist stereotypes, which can...
Researchers at Temple University Health System report that the BASHIR Endovascular Catheter reduces blockages in lung arteries and correlates with improved right ventricle function, suggesting better survival outcomes. The catheter also shows significantly lower bleeding rates compared to other devices.
A new NIH grant will investigate how news media reports on community firearm violence affect survivors, communities, and policymakers. The research aims to develop evidence-based guidelines for safer reporting, inspired by successful approaches for other traumatic events.
Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.
A new NIH grant will investigate the impact of combined alcohol and e-cigarette use on the blood brain barrier, a cell layer regulating substance passage into the central nervous system. The study aims to identify mechanisms behind damage and potential biomarkers for clinical use.
A novel CRISPR-based gene-editing treatment, EBT-001, effectively removes SIV from the genomes of non-human primates without off-target effects. The study's findings support the development of a cure for HIV/AIDS in humans and pave the way for ongoing clinical trials.
Researchers at Temple University Health System discovered a promising alternative to control hypertension and associated cardiovascular problems. The infused juice concentrate from the Japanese plum was found to attenuate growth-promoting signals induced by angiotensin II, reducing hypertrophy of the aorta and inflammation.
Scientists at Temple University have developed a novel gene-editing strategy that disrupts the ability of HIV-1 virus to enter host cells by targeting a rare genetic disorder. This approach may offer another target for developing next-generation CRISPR technology for HIV elimination, while avoiding adverse effects on cell mortality.
Researchers at the Lewis Katz School of Medicine found that calcium sensor MICU1 regulates mitochondrial ultrastructure, governing inner and outer mitochondrial membrane structure. This discovery provides a framework for understanding cellular energetics and cell death, with implications for diseases such as cardiovascular disease.
Researchers at Temple University and the University of Nebraska Medical Center developed a novel dual gene-editing approach that can effectively eliminate HIV infection. The therapy targets both HIV-1, the virus responsible for AIDS, and CCR5, a co-receptor that facilitates viral entry into cells.
Researchers at Temple University Health System found that carbonic anhydrase inhibitors reduce inflammation, restore cell function and prevent cognitive impairment in mice with amyloid buildup. CAIs also improved cerebrovascular health and enhanced amyloid-clearing capacity.
A novel treatment approach called balloon pulmonary angioplasty has been shown to be effective in treating chronic blood clots in lung arteries. The procedure improves exercise capacity and quality of life, with some patients able to stop medications altogether. Refinements in technique have improved the procedure's safety and efficacy.
Researchers at Temple University and Johns Hopkins University found that brain-derived neurotrophic factor (BDNF) loss underlies post-myocardial infarction heart failure. BDNF levels can be replenished therapeutically, abolishing damage to heart tissue and enabling recovery.
A new approach to boosting protein production has been discovered, which could lead to the generation of a universal booster for protein production. The breakthrough centers on Exin21, a sequence that increases mRNA synthesis and stability and protein expression and secretion.
A Temple-led study explores how recently firearm-injured individuals perceive news media coverage of their injuries and firearm violence. Participants reported feeling relieved when not
Researchers at Temple University will use a participatory action research model to study urban gun violence in Philadelphia, targeting individuals in at-risk communities. The goal is to gain new insight into factors contributing to street violence and strengthen public health interventions.
The study aims to assess the effectiveness of recombinant Factor VIIa (rFVIIa) in decreasing bleeding in the brain of patients with intracerebral hemorrhage (ICH). ICH is a deadly stroke type with no effective treatment, and this trial seeks to improve outcomes.
Researchers from Temple University Health System developed a device that significantly reduces blood clot size in pulmonary arteries, leading to improved heart function and shorter treatment duration. The breakthrough is based on data collected in the NIH-sponsored RESCUE trial.